Japanese Gastric Cancer Association

Gastric Cancer · 2011–2022

A researcher in the Science corpus: 5 papers; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Whom Japanese Gastric Cancer Association trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Leslie Sobin

Papers from Japanese Gastric Cancer Association's perspective

Ordered by how strongly the researchers Japanese Gastric Cancer Association trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. (New England Journal of Medicine)
  2. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised… (The Lancet)
  3. Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers (Gastric Cancer)
  4. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. (New England Journal of Medicine)
  5. PD-1 blockade in tumors with mismatch repair deficiency. (Journal of Clinical Oncology)
  6. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroœsophageal junction
  7. TNM Classification of Malignant Tumours, 7th Edition
  8. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. (The Lancet)
  9. Capecitabine and oxaliplatin for advanced esophagogastric cancer. (New England Journal of Medicine)
  10. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. (Journal of Clinical Oncology)

Their papers